For general inquiries, call 1 877-564-0008 or [email protected]. Fax PoNS device prescriptions to 1 (215) 754-4903.

Author: ponsus

Helius Medical Technologies, Inc. Announces Online Training for PoNS Therapy™

– Training for physical therapists treating patients with multiple sclerosis (MS) is now available on demand – NEWTOWN, Pa., July 12, 2022 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the launch of its online training module for physical therapists seeking to […]

Helius Medical Technologies, Inc. Presents Poster at the 2022 Consortium of Multiple Sclerosis Centers (“CMSC”) Annual Meeting

– Study finds significant improvement in gait deficit in multiple sclerosis patients using translingual neurostimulation (“PoNS Therapy®”) combined with a therapeutic exercise program – – Poster was one of ten rehabilitation research presentations nominated for the Labe C. Scheinberg Award recognizing the platform or poster, in each therapeutic category, that has the greatest impact in advancing the care […]

Helius Medical Technologies, Inc. Announces Launch of Patient Therapy Access Program for PoNS®

New program seeks to expand access to patients suffering from multiple sclerosis (MS) NEWTOWN, Pa., June 01, 2022 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the launch of its Patient Therapy Access Program (“PTAP”), which will provide qualifying patients access to […]

Helius Medical Announces Poster to Be Presented at the Consortium for Multiple Sclerosis Centers (CMSC) Annual Conference

NEWTOWN, Pa., May 31, 2022 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that an abstract highlighting real-world data, which shows the impact of translingual neurostimulation as a rehabilitation therapy to improve gait in people with multiple sclerosis (MS), has been […]

Helius Medical Technologies, Inc. Reports First Quarter 2022 Financial Results and Provides Update on U.S. Commercial Launch of PoNS®

– Company to host call at 9:00am today with CEO, CFO, CMO and VP Sales & Marketing – NEWTOWN, Pa., May 12, 2022 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter ended March 31, 2022. First Quarter and […]

Helius Medical Technologies, Inc. Fulfills First U.S. Prescriptions for PoNS®

– First patients have purchased PoNS devices to initiate PoNS Therapy –– Nineteen PoNS device prescriptions have been written in the U.S. since recent commercial launch – NEWTOWN, Pa., April 27, 2022 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the fulfillment […]

Helius Medical Technologies, Inc. Introduces Device in U.S. To Help Multiple Sclerosis Patients Improve Walking Ability

– Breakthrough technology for MS patients helps patients with gait deficit – Portable Neuromodulation Stimulator (PoNS®) is an innovative non-surgical medical device that includes a controller and a mouthpiece – Available directly to patients by prescription, used in conjunction with physical therapy NEWTOWN, Pa., April 26, 2022 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq: […]

Helius Medical Technologies, Inc. Announces Issuance of U.S. Patent for Wireless PoNS®

Patent Readies Company for Next Generation of PoNS Therapy NEWTOWN, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (Helius or the Company), a neurotech company focused on neurological wellness, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,197,994, which is directed to systems […]

Helius Medical Technologies, Inc. Launches Therapeutic Experience Program; NYU Langone Health Is Initial Clinical Trial Site

– Multi-center, company-sponsored, open label observational interventional trial to evaluate impact of subjects’ adherence to PoNS® therapy for gait improvement in Multiple Sclerosis –– Program to include 10-12 U.S. Centers of Excellence; enrollment to commence in Q4 2021 – NEWTOWN, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the […]

Helius Medical, Inc. Receives U.S. Marketing Authorization for the PoNS™ Device

First and only tongue-delivered neuromodulation therapy provides new treatment option for U.S. patients living with gait deficit due to symptoms from multiple sclerosis NEWTOWN, Pa., March 29, 2021 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that its wholly owned subsidiary, […]

For Patients

Subscribe to our newsletter

For general inquiries, contact us by phone at 1 877-564-0008 or via email at [email protected].

Please fax PoNS device prescriptions to 1 (215) 754-4903.

Facebook Linkedin Youtube

NASDAQ: HSDT

Indications

The PoNS® device is indicated for use as a short term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis and is to be used as an adjunct to a supervised therapeutic exercise program for adults 22 years of age and over by prescription only.

Contraindications

The PoNS® device delivers electrical stimulation directly to the surface of the tongue. Precautions for use are similar to those for transcutaneous electrical nerve stimulation (TENS).

Electrical stimulation should not be used:

  • If there is an active or suspected malignant tumor
  • In areas of recent bleeding or open wounds
  • In areas that lack normal sensation
The PoNS® has not been tested on, and thus should not be used by individuals who are pregnant. Do not use the PoNS® if you are sensitive to nickel, gold or copper.
Please review the Important Safety Information.

© Copyright 2024 | Helius Medical Technologies.

By submitting this form, you agree to receive future updates and communication regarding the PoNS® device and other Helius products, services, programs or topics of interest. Your consent is not required as a condition of receiving any goods or services from Helius. You may choose unsubscribe and choose not to receive further information from Helius by emailing [email protected]

IMPORTANT SAFETY INFORMATION

No serious adverse events related to the PoNS device were reported in the MS RCTs or in use in clinical rehabilitation settings to treat balance and gait disorders.

Some individuals have reported headaches, fatigue, and excess salivation. Excess salivation during training sessions often occurs but generally improves as patients get used to wearing the mouthpiece.

Indication
The PoNS® device is indicated for use as a short term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis and is to be used as an adjunct to a supervised therapeutic exercise program for adults 22 years of age and over by prescription only.

Contraindications
The PoNS® device delivers electrical stimulation directly to the surface of the tongue. Precautions for use are similar to those for transcutaneous electrical nerve stimulation (TENS).

Electrical stimulation should not be used:

  • If there is an active or suspected malignant tumor
  • In areas of recent bleeding or open wounds
  • In areas that lack normal sensation

The PoNS® has not been tested on, and thus should not be used by individuals who are pregnant. Do not use the PoNS® if you are sensitive to nickel, gold or copper.

Use with caution
Electrical stimulation should only be used after seeking professional medical advice, and with caution in patients with any of the following:

  • Implanted electronic devices, including:
    • Cardiac pacemakers
    • Cardioverter defibrillators
    • Deep Brain Stimulators
    • Vagal Nerve Stimulators
    • Sacral nerve stimulators
    • Cochlear Implants
  • Metal in the mouth (e.g. piercings, braces, retainers, or other orthodontic appliance)
  • Seizure disorders
  • Epilepsy

Ready to get started with PoNS?

Patients who are seeking more information on how to get PoNS can email us at [email protected], or fill out our contact form:

Contact Us